ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / MAIA / insiders
TELO (28) TENX (27) SDEV (33) ACRV (33) ⌘ Pro Terminal β†’

MAIA Biotechnology Inc. (MAIA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.08 -1.82% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.07

MAIA Biotechnology Inc. (MAIA) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $67.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MAIA Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is MAIA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, MAIA Biotechnology Inc. (NYSE: MAIA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.08 (-1.82% 1D, market cap $67.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MAIA ranks #724 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does MAIA compare to TELO and TENX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MAIA carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, TELO (Telomir Pharmaceuticals Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M) and TENX (Tenax Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M). Among the 5-stock peer group, MAIA leads on earnings multiple (N/A) while MAIA leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MAIA?
β–Ό

Per MAIA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001878313), MAIA Biotechnology Inc. generated $68.0M in revenue (+43.1% YoY), -$22.4M in net income, and -$18.8M in free cash flow against $9.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.07 (-0.52%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (32/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510032
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (6)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12% Base Target
$3 Bull$1 Base$1 Bear
πŸ“¬ FREE MAIA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for MAIA)Realized 20D OHLCV Swing Band: Β±10.4%
Deterministic 5-Pillar Attribution (32/100 Composite)
πŸ” WHY MAIA SCORES 32/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–² #2 Bullish Driver: Macro Regime Fit+8/20 pts (25% of score)

FRED Regime Γ— Technicals: 9% of 52W Range β€’ RSI-14 at 42.2 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
40
Grade D$1.12+1.8% Next Q
Q2 (-2Q)
37
Grade E$1.14+1.8% Next Q
Q3 (-1Q)
35
Grade E$1.16-6.9% Next Q
Current
32
Grade E$1.08-9.2% Hist 90D Ξ±
Trajectory: D (40) β†’ E (32)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a MAIA Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While MAIA currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.23) and Max Pain ($1.13) forces dealer call-delta covering toward $3.35.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MAIAβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œMAIA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

MAIA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (MAIA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on MAIA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MAIA)

  • βœ“Walkthrough of MAIA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
MAIA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.30%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-04O $1.10H $1.10L $1.08C $1.08VOL 151.7K
RES: $1.40SUP: $1.04SMA50: $1.23SMA200: $1.45
$1.60$1.45$1.31$1.16$1.02RES $1.40SUP $1.04$1.082026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MAIA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ MAIA Butterfly Map β†’ + Track MAIA β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +43.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MAIA today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for MAIA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MAIA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MAIA)

Health Care Rank #724 of 1015 βš”οΈ TELO vs MAIA Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (MAIA vs. TELO, TENX, SDEV, ACRV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, MAIA Biotechnology Inc. (MAIA) ranks #724 by composite RQD confidence (32/100, grade E) and #698 by equity capitalization ($67.9M). Within this direct 5-issuer industry benchmark cohort, MAIA leads on earnings valuation at N/A trailing P/E, while MAIA leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. SDEV currently holds the highest overall quantitative score in the immediate peer group at 33/100 (E) compared with MAIA at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MAIA ACTIVE
MAIA Biotechnology Inc.
E 32/100 β€” β€” -35.0% -1.82% $67.9M Benchmark Subject
TELO
Telomir Pharmaceuticals Inc.
E 28/100 β€” β€” -35.0% -0.56% $67.4M /telo-vs-maia β†’
TENX
Tenax Therapeutics Inc.
E 27/100 β€” β€” -35.0% +2.22% $67.4M /tenx-vs-maia β†’
SDEV
Stablecoin Development Corporation
E 33/100 β€” β€” -35.0% +3.26% $67.3M /sdev-vs-maia β†’
ACRV
Acrivon Therapeutics Inc.
E 33/100 β€” β€” -35.0% +3.73% $69.0M /acrv-vs-maia β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001878313 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MAIA Biotechnology Inc. (MAIA) reported GAAP revenue of $68.0M (+43.1% vs. FY2024 revenue of $47.5M ) , GAAP net income of -$22.4M, operating cash flow of -$18.8M, and free cash flow of -$18.8M (-20.0% YoY). On the balance sheet, MAIA closed FY2025 with $9.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $68.0M -$22.4M -$18.8M -$18.8M $9.7M β€”
FY2024 (FY) 2024-12-31 $47.5M -$23.3M -$15.7M -$15.7M $10.2M β€”

3. MAIA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MAIA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, MAIA Biotechnology Inc. (NYSE: MAIA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.08 (-1.82% 1D, market cap $67.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MAIA ranks #724 in composite RQD confidence.

How does MAIA compare to TELO and TENX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MAIA carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, TELO (Telomir Pharmaceuticals Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M) and TENX (Tenax Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M). Among the 5-stock peer group, MAIA leads on earnings multiple (N/A) while MAIA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MAIA?

Per MAIA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001878313), MAIA Biotechnology Inc. generated $68.0M in revenue (+43.1% YoY), -$22.4M in net income, and -$18.8M in free cash flow against $9.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MAIA trading relative to its 50-day, 200-day, and 52-week technical levels?

MAIA last traded at $1.08 (-1.82% on volume of 174,243 shares), positioning the stock -12.20% below its 50-day simple moving average ($1.23) and -25.52% below its 200-day simple moving average ($1.45). Across its 52-week range of $0.87 to $3.19, MAIA sits at the 9.1% percentile with a 14-day RSI of 42.2 (NEUTRAL RANGE) and an implied next-earnings move of Β±10.4% ($1.00 to $1.19).

Direct Sub-Reports: MAIA RQD Cockpit MAIA 12M Forecast MAIA Earnings & Move MAIA Dividends & DRIP MAIA Insiders & 13F MAIA Whale Options MAIA Profit Sankey MAIA News & Why
ROARABLE RATING BRIEF β€’ RQD 32/100 (E) βœ“ SEC XBRL & RQD VERIFIED

MAIA β€” MAIA Biotechnology Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

MAIA Biotechnology Inc. (MAIA) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.08 (-1.82% 1D, market capitalization $67.9M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

MAIA Biotechnology Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company's market capitalization is $0.1B. Per the recent news wire, the company is advancing patient enrollment in Phase 2 and pivotal Phase 3 clinical trials in non-small cell lung cancer.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), MAIA Biotechnology Inc. (MAIA) reported $68.0M in annual revenue (up from $47.5M in FY2024, +43.1% YoY) and -$22.4M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($47.5M revenue, -$23.3M net income) through FY2025, MAIA scaled operating cash flow to -$18.8M and free cash flow to -$18.8M, backed by $9.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.87 – $3.19 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MAIA carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can MAIA sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $68.0M and free cash flow of -$18.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MAIA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MAIA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for MAIA Biotechnology Inc. (MAIA) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to MAIA Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MAIA Bull vs. Bear Conversation Board β€” What's Your Call at $1.08?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MAIA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MAIA:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $1.34 (+21.8%)
πŸ“Œ Pinned Debate

Enrollment milestones in Phase 2 and pivotal Phase 3 non-small cell lung cancer trials are the only cited near-term catalyst, and the s

Picked up a starter position in MAIA in my $100K Virtual Cash book at $1.10. Enrollment milestones in Phase 2 and pivotal Phase 3 non-small cell lung cancer trials are the only cited near-term catalyst, and the stock trades 65% above its $0.87 52-week low.. Trading inside a $0.87–$3.19 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator πŸ‚ BULL

@DeltaGamma_99 Agree on the RQD 32/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.10 and keeping dry powder in case we test $1.02.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $0.87 (-20.9%)
Spot @ $1.10

With $0.0M reported revenue, ROIC of -35%, and 0% FCF yield, the RQD rating scores the company's cash engine at only 6 out of 20.

Fading this rally in MAIA at $1.10. With $0.0M reported revenue, ROIC of -35%, and 0% FCF yield, the RQD rating scores the company's cash engine at only 6 out of 20.. With a beta of 1.0 and the stock sitting at $1.10 (52-wk range $0.87–$3.19), the easy multiple expansion is already priced in.

LIVE TAPE